Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy

被引:2
|
作者
Higashiyama, Tomoaki [1 ]
Ohji, Masahito [1 ]
机构
[1] Shiga Univ Med Sci, Dept Ophthalmol, Tsukinowa Cho, Otsu, Shiga 5202192, Japan
来源
CLINICAL OPHTHALMOLOGY | 2018年 / 12卷
关键词
bimatoprost; thyroid-associated ophthalmopathy; exophthalmos; orbital fat;
D O I
10.2147/OPTH.S187164
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: This study was performed to observe changes prospectively in exophthalmos and orbital fat in patients with inactive thyroid-associated ophthalmopathy (TAO) treated with bimatoprost. Methods: In this 12-month single-treatment pilot observational study, 13 patients with inactive-phase TAO were administered bimatoprost to treat exophthalmos due to TAO. Exophthalmos values and orbital tissue volumes were measured on MRI by technicians in a masked fashion. Results: Nine orbits of nine patients (eight women, one man) were treated with bimatoprost for 12 months. Mean exophthalmos values before and after treatment were 21.7 +/- 2.2 and 21.7 +/- 2.0 mm, respectively. The mean value after 12 months of treatment was not significantly different from before treatment (P=0.82). Mean orbital fat volume before and after 12 months of treatment was 17.2 +/- 2.5 and 17.0 +/- 3.0 cm(3), respectively. The corresponding total extraocular muscle volume was 4.0 +/- 0.7 and 3.8 +/- 0.9 cm(3), respectively. Mean volume in each tissue type after 12 months of treatment was not significantly different from before treatment (orbital fat, P=0.70; extraocular muscles, P=0.32). Conclusion: Topical bimatoprost treatment did not reduce exophthalmos or orbital fat in this cohort of patients with inactive TAO.
引用
收藏
页码:2415 / 2421
页数:7
相关论文
共 50 条
  • [21] Progress in thyroid-associated ophthalmopathy
    Wall, J
    Kennerdell, JS
    AUTOIMMUNITY, 1995, 22 (03) : 191 - 195
  • [22] GLYCOSAMINOGLYCANS IN THYROID-ASSOCIATED OPHTHALMOPATHY
    KAHALY, G
    STOVER, C
    OTTO, E
    BEYER, J
    SCHULER, M
    AUTOIMMUNITY, 1992, 13 (01) : 81 - 88
  • [23] Rituximab for thyroid-associated ophthalmopathy
    Kang, Swan
    Azzam, Shirin Hamed
    Minakaran, Neda
    Ezra, Daniel G.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
  • [24] Cytokines in Thyroid-Associated Ophthalmopathy
    Zhang, Pengbo
    Zhu, Huang
    JOURNAL OF IMMUNOLOGY RESEARCH, 2022, 2022
  • [25] Octreoscan in thyroid-associated ophthalmopathy
    Krassas, GE
    THYROID, 2002, 12 (03) : 229 - 231
  • [26] Teprotumumab for Thyroid-Associated Ophthalmopathy
    Smith, Terry J.
    Kahaly, George J.
    Ezra, Daniel G.
    Fleming, James C.
    Dailey, Roger A.
    Tang, Rosa A.
    Harris, Gerald J.
    Antonelli, Alessandro
    Salvi, Mario
    Goldberg, Robert A.
    Gigantelli, James W.
    Couch, Steven M.
    Shriver, Erin M.
    Hayek, Brent R.
    Hink, Eric M.
    Woodward, Richard M.
    Gabriel, Kathleen
    Magni, Guido
    Douglas, Raymond S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (18): : 1748 - 1761
  • [27] Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy
    Li, Zilin
    FRONTIERS IN ENDOCRINOLOGY, 2025, 15
  • [28] Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab
    Canas, Carlos A.
    Bonilla-Abadia, Fabio
    Vallejo, Katherine
    Rengifo, Hector M.
    Gallon, Marco A.
    Tobon, Gabriel. J.
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2018, 18 (06) : 665 - 667
  • [29] Reduced cortical complexity in patients with thyroid-associated ophthalmopathy
    Jiang Zhou
    Wen Chen
    Qian Wu
    Lu Chen
    Huan-Huan Chen
    Hu Liu
    Xiao-Quan Xu
    Fei-Yun Wu
    Hao Hu
    Brain Imaging and Behavior, 2022, 16 : 2133 - 2140
  • [30] Clinical Characteristics of Patients with Euthyroid Thyroid-associated Ophthalmopathy
    Kim, Sang Yoon
    Ahn, Jung Hyo
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2022, 63 (09): : 741 - 746